Dosing Bupropion and Topiramate for Weight Loss in a 28-Year-Old Male
Do not prescribe bupropion and topiramate together as separate medications—this combination significantly increases seizure risk and causes serious neuropsychiatric complications. 1
Critical Safety Issue: Avoid This Combination
The combination of bupropion with topiramate creates dangerous drug interactions that include:
- Increased seizure risk due to both medications lowering the seizure threshold 1
- Cognitive impairment with worsening concentration and memory problems 1
- Enhanced neuropsychiatric adverse effects including anxiety and panic attacks 1
Recommended Alternative Approaches
Option 1: FDA-Approved Phentermine/Topiramate ER (Qsymia) - Preferred Choice
Use the FDA-approved fixed-dose combination phentermine/topiramate ER instead of prescribing these as separate agents. 2
Dosing schedule:
- Week 1-2: Start 3.75 mg phentermine/23 mg topiramate ER once daily in the morning 2
- Week 3 onward: Increase to 7.5 mg/46 mg once daily 2
- Week 12 assessment: If <3% weight loss achieved, escalate to 11.25 mg/69 mg daily 2
- Maximum dose: 15 mg/92 mg daily if needed 2
Discontinuation criteria:
- Stop if <3% weight loss at 12 weeks on the 7.5/46 mg dose 2
- Stop if <5% weight loss at 12 weeks on the 15/92 mg dose 2
Expected weight loss: 9.8% total body weight loss at one year on the maximum dose 3, 4
Option 2: Bupropion/Naltrexone SR (Contrave) - Alternative Without Topiramate
If you prefer bupropion for its antidepressant properties, use the FDA-approved bupropion/naltrexone SR combination instead. 2
Dosing schedule:
- Week 1: 1 tablet (8 mg naltrexone/90 mg bupropion) once daily in the morning 2
- Week 2: 1 tablet twice daily (morning and evening) 2
- Week 3: 2 tablets in morning, 1 tablet in evening 2
- Week 4 onward: 2 tablets twice daily (maximum dose: 32 mg naltrexone/360 mg bupropion total daily) 2
Discontinuation criteria:
- Stop if <5% weight loss at 12 weeks 2
Expected weight loss: 5-6.1% total body weight loss at 56 weeks 5, 4
Option 3: Bupropion Monotherapy - If Combination Therapy Contraindicated
Bupropion alone produces modest weight loss of 2.77 kg at 6-12 months. 6, 7
Standard dosing for weight loss effect uses doses similar to those for depression or smoking cessation, though specific weight loss dosing is not FDA-approved for monotherapy. 7
Special Considerations for This Patient's History
Colostomy Considerations
Avoid orlistat entirely in patients with colostomy due to:
- Severe gastrointestinal side effects with steatorrhea 2
- Malabsorption of fat-soluble vitamins 2
- Potential complications with ostomy management
Hernia Considerations
- Phentermine/topiramate ER and bupropion/naltrexone SR have no specific contraindications related to hernia history 2
- Weight loss itself will reduce intra-abdominal pressure and hernia recurrence risk 5
Diverticulitis History
- No specific contraindications for either medication combination with resolved diverticulitis 2
- Weight loss improves overall gastrointestinal health 5
Contraindications to Screen For
Before prescribing phentermine/topiramate ER, exclude: 3, 8
- Uncontrolled hypertension
- Cardiovascular disease
- Hyperthyroidism
- Glaucoma
- History of drug abuse
- MAOI use within 14 days
- Pregnancy (teratogenic risk—requires negative pregnancy test and contraception) 8
Before prescribing bupropion/naltrexone SR, exclude: 2
- Uncontrolled hypertension
- Seizure history or conditions predisposing to seizures
- Eating disorders (bulimia/anorexia)
- Opioid dependence or current opioid use
- Abrupt discontinuation of alcohol or benzodiazepines
Monitoring Requirements
For phentermine/topiramate ER: 1
- Baseline and periodic: electrolytes, creatinine, blood pressure, heart rate
- Monitor for: cognitive impairment, mood changes, suicidal ideation, metabolic acidosis
For bupropion/naltrexone SR: 2
- Baseline and periodic: blood pressure, heart rate
- Monitor for: seizures, neuropsychiatric symptoms, hepatotoxicity
Essential Counseling Points
All pharmacotherapy must be combined with:
- Medical nutrition therapy with calorie restriction 5, 3
- Physical activity (≥150 minutes/week moderate-intensity exercise) 5
- Behavioral interventions including self-monitoring 5
Common pitfall to avoid: Never prescribe bupropion and topiramate as separate medications thinking you can replicate the FDA-approved combination—the interaction profile is dangerous and this approach is not evidence-based. 1